Back to Journals » International Medical Case Reports Journal » Volume 10

Diabetic papillopathy treated with intravitreal ranibizumab

Authors Yildirim M, Kilic D, Dursun ME, Dursun B

Received 16 January 2017

Accepted for publication 21 February 2017

Published 22 March 2017 Volume 2017:10 Pages 99—103

DOI https://doi.org/10.2147/IMCRJ.S132479

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Dr Scott Fraser


Mine Yildirim, Deniz Kilic, Mehmet Emin Dursun, Birgul Dursun

Department of Ophthalmology, Gazi Yasargil Training and Research Hospital, Diyarbakır, Turkey

Abstract: In this report, we present a case of diabetic papillopathy that resolved after a single dose of intravitreal ranibizumab injection. A 50-year-old male presented with painless visual loss in his right eye. His visual acuity was 1/10 in the right eye and 10/10 in the left eye. Anterior segment examination of both eyes was unremarkable. Posterior segment of the right eye showed nonproliferative diabetic retinopathy with a swollen optic disc. Fluorescein angiography and optical coherence tomography were performed. There was dye leakage from the right optic disc. Optical coherence tomography revealed a significant increase in retinal nerve fiber layer thickness. Magnetic resonance imaging of the brain and orbit were normal. The patient received a single intravitreal ranibizumab (0.5 mg) injection. Two weeks after the injection, there was a marked regression of the disc swelling. Three months after the injection the optic disc was pallor and visual acuity was 6/10.

Keywords: diabetic papillopathy, optic disc swelling, ranibizumab, optical coherence tomograpy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]